<DOC>
	<DOCNO>NCT00453115</DOCNO>
	<brief_summary>Oxaliplatin diaminocyclohexane platinum compound , mechanism action similar cisplatin . Oxaliplatin manageable toxicity profile cisplatin , renal toxicity lower incidence hematological gastrointestinal toxicity . Gemcitabine oxaliplatin active NSCLC overlap toxicity . Preclinical study show synergistic effect gemcitabine-oxaliplatin combination . The combination gemcitabine-oxaliplatin attractive NSCLC patient may improve therapeutic index .</brief_summary>
	<brief_title>Gemcitabine Plus Oxaliplatin Advanced Stage IIIB/IV Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>The combination gemcitabine-oxaliplatin attractive NSCLC patient may improve therapeutic index . We conduct phase II study evaluate response rate toxicity gemcitabine-oxaliplatin combination give every 4 week patient advance NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Histologic cytologic diagnosis NSCLC , Stage IV select stage IIIB ( positive pleural effusion separate tumor nodule lobe ) accord American Joint Committee Cancer ( AJCC ) . 2 . No prior chemotherapy . 3 . Prior radiation therapy allow long irradiated area source measurable disease . 4 . No forms cancer therapy , radiation , immunotherapy least 4 week enrollment study . 5 . Performance status 0 , 1 , 2 ECOG criterion . 6 . At least one unidimensional measurable lesion meeting Response Evaluation Criteria Solid Tumors ( RECIST . 2000 ) . 7 . Estimated life expectancy least 12 week . 8 . Patient compliance allow adequate followup . 9 . Adequate organ function include follow : Adequate hematologic function : WBC count ≥ 3,500/uL , absolute neutrophil count ( ANC ) ≥ 1,500/uL , platelet count ≥ 100,000/uLAdequate hepatic function : bilirubin ≤ 1.5 x UNL , ALT AST ≤ 2.5 x UNL.Adequate renal function : creatinine ≤ 1.5mg/dL . 10 . Informed consent patient 11 . Males female least 18 year old . 12 . If female : childbearing potential either terminate surgery , radiation , menopause , attenuate use approve contraceptive method ( intrauterine device [ IUD ] , birth control pill , barrier device ) 3 month trial . If male , use approve contraceptive method study 3 month afterwards . Females childbearing potential must urine negative hCG test within 7 day prior study registration . 1 . MI within precede 6 month symptomatic heart disease , include unstable angina , congestive heart failure uncontrolled arrhythmia 2 . Serious concomitant infection include post obstructive pneumonia 3 . Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin prior malignancy treat 5 year ago without recurrence ) 4 . Pregnant nursing woman 5 . Psychiatric disorder would preclude compliance . 6 . Major surgery biopsy within past two week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>advanced stage IIIB</keyword>
	<keyword>Stage IV</keyword>
</DOC>